280 related articles for article (PubMed ID: 23818108)
1. A new treatment paradigm for trigeminal neuralgia using Botulinum toxin type A.
Guardiani E; Sadoughi B; Blitzer A; Sirois D
Laryngoscope; 2014 Feb; 124(2):413-7. PubMed ID: 23818108
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial.
Wu CJ; Lian YJ; Zheng YK; Zhang HF; Chen Y; Xie NC; Wang LJ
Cephalalgia; 2012 Apr; 32(6):443-50. PubMed ID: 22492424
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin in trigeminal neuralgia.
Castillo-Álvarez F; Hernando de la Bárcena I; Marzo-Sola ME
Med Clin (Barc); 2017 Jan; 148(1):28-32. PubMed ID: 27743594
[TBL] [Abstract][Full Text] [Related]
4. OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data.
Kowacs PA; Utiumi MA; Nascimento FA; Piovesan EJ; Teive HA
Arq Neuropsiquiatr; 2015 Oct; 73(10):877-84. PubMed ID: 26291995
[TBL] [Abstract][Full Text] [Related]
5. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report.
Bohluli B; Motamedi MH; Bagheri SC; Bayat M; Lassemi E; Navi F; Moharamnejad N
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Jan; 111(1):47-50. PubMed ID: 20674409
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin.
Gazerani P; Pedersen NS; Staahl C; Drewes AM; Arendt-Nielsen L
Pain; 2009 Jan; 141(1-2):60-9. PubMed ID: 19004549
[TBL] [Abstract][Full Text] [Related]
7. A new target for the treatment of trigeminal neuralgia with botulinum toxin type A.
Wu C; Xie N; Liu H; Zhang H; Zhang L; Lian Y
Neurol Sci; 2018 Mar; 39(3):599-602. PubMed ID: 29086125
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of botulinum toxin for the treatment of trigeminal and postherpetic neuralgia: a systematic review with meta-analyses.
Shackleton T; Ram S; Black M; Ryder J; Clark GT; Enciso R
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Jul; 122(1):61-71. PubMed ID: 27260275
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin and intractable trigeminal neuralgia.
Türk U; Ilhan S; Alp R; Sur H
Clin Neuropharmacol; 2005; 28(4):161-2. PubMed ID: 16062093
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials.
Wei J; Zhu X; Yang G; Shen J; Xie P; Zuo X; Xia L; Han Q; Zhao Y
Brain Behav; 2019 Oct; 9(10):e01409. PubMed ID: 31541518
[TBL] [Abstract][Full Text] [Related]
11. Botulinum neurotoxin type A in the treatment of classical Trigeminal Neuralgia (BoTN): study protocol for a randomized controlled trial.
Burmeister J; Holle D; Bock E; Ose C; Diener HC; Obermann M
Trials; 2015 Dec; 16():550. PubMed ID: 26634453
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
14. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial.
Zhang H; Lian Y; Ma Y; Chen Y; He C; Xie N; Wu C
J Headache Pain; 2014 Sep; 15(1):65. PubMed ID: 25263254
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin type A applications for masticatory myofascial pain and trigeminal neuralgia: what is the evidence regarding adverse effects?
De la Torre Canales G; Poluha RL; Lora VM; Araújo Oliveira Ferreira DM; Stuginski-Barbosa J; Bonjardim LR; Cury AADB; Conti PCR
Clin Oral Investig; 2019 Sep; 23(9):3411-3421. PubMed ID: 31342244
[TBL] [Abstract][Full Text] [Related]
16. Unilateral facial injection of Botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice.
Chen WJ; Niu JQ; Chen YT; Deng WJ; Xu YY; Liu J; Luo WF; Liu T
J Headache Pain; 2021 May; 22(1):38. PubMed ID: 34000998
[TBL] [Abstract][Full Text] [Related]
17. Regional Targeted Subcutaneous Injection of Botulinum Neurotoxin Type A in Refractory Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study.
Bono F; Mazza MR; Magro G; Spano G; Idone G; Laterza V; Tedeschi D; Pucci F; Gambardella A; Sarica A
Toxins (Basel); 2023 May; 15(5):. PubMed ID: 37235358
[TBL] [Abstract][Full Text] [Related]
18. Is botulinum toxin A effective for the treatment of plantar fasciitis?
Peterlein CD; Funk JF; Hölscher A; Schuh A; Placzek R
Clin J Pain; 2012 Jul; 28(6):527-33. PubMed ID: 22673486
[TBL] [Abstract][Full Text] [Related]
19. Botulinum Toxin Type A Injections as an Effective Treatment of Refractory Multiple Sclerosis-Related Trigeminal Pain - A Case Report.
Calejo M; Salgado P; Moreira B; Correia C; Barros J
Headache; 2019 Sep; 59(8):1379-1381. PubMed ID: 31424566
[No Abstract] [Full Text] [Related]
20. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
Dressler D; Bigalke H; Benecke R
J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
